top of page
.jpg)
Restoring immune function unlocking the full potential of immunotherapy
Nearly half of people with cancer rely on opioids for pain.
But opioids suppress the immune system and block the effectiveness of immunotherapy. Our lead drug restores immune response without interfering with pain relief unlocking better outcomes.
At Glycyx, we aim to significantly improve survival rates and quality of life for cancer patients worldwide by developing innovative therapies that restore immune function.
What we do
As a biotechnology firm ready for Phase 2, Glycyx is pioneering a novel therapeutic solution that restores immune function and enables T-cell infiltration into tumors when used in combination with immune checkpoint inhibitors. We reverse the negative effects of opioids without compromising pain relief and amplify the effectiveness of anti-PD1/PD-L1 cancer treatments. Our mission is to significantly improve survival rates and quality of life for cancer patients worldwide.
bottom of page